Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 114 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thrombosis; Artery Clear all
Recruiting No phase listed Observational

Vascular Lab Resource (VLR) Biorepository

NCT05628948
View directory record Official record
Conditions
Cardiovascular Diseases, Metabolic Disease, Peripheral Artery Disease, Carotid Disease, Aneurysmal Disease, Venous Disease, Thrombosis, Lymphedema, Lipedema, Non-Atherosclerotic Chronic Arterial Occlusive Disease, Vasculitis, Fibromuscular Dysplasia, Arterial Dissection, May-Thurner Syndrome, Thoracic Outlet Syndrome, Vasospasm
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
500 participants
Timeline
2019 – 2031
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Sep 30, 2026, 9:30 PM EDT
Completed Not applicable Interventional

GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety

NCT00645918
View directory record Official record
Conditions
Coronary Arteriosclerosis, Acute Coronary Syndrome
Interventions
clopidogrel, placebo
Drug
Lead sponsor
Accumetrics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
72
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Sep 30, 2026, 9:30 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

NCT02889562
View directory record Official record
Conditions
Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation, Stroke, Systemic Embolism, Deep Venous Thrombosis
Interventions
Apixaban, Warfarin
Drug
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Sep 30, 2026, 9:30 PM EDT
Not listed No phase listed Observational

EKG Criteria and Identification of Acute Coronary Occlusion

NCT03863327
View directory record Official record
Conditions
Acute Coronary Syndrome, STEMI, STEMI - ST Elevation Myocardial Infarction, Acute Coronary Artery Thrombosis (Diagnosis), NSTEMI - Non-ST Segment Elevation MI, Non-ST Elevation Myocardial Infarction, Non ST Segment Elevation Myocardial Infarction, Non ST Segment Elevation Acute Coronary Syndrome, Non-ST Elevation Myocardial Infarction (nSTEMI), Non STEMI
Interventions
No intervention
Other
Lead sponsor
Stony Brook University
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 30, 2026, 9:30 PM EDT
Completed Not applicable Interventional

LV Thrombus Pilot Study for Comparing Enoxaparin Vs. Warfarin

NCT00321009
View directory record Official record
Conditions
Coronary Artery Disease, Acute Myocardial Infarction
Interventions
Enoxaparin
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
6
States / cities
Denver, Colorado • Royal Oak, Michigan • Syracuse, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 3, 2006 · Synced Sep 30, 2026, 9:30 PM EDT
Completed Not applicable Interventional Results available

An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System

NCT01638507
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Resolute Integrity Stent
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Sep 30, 2026, 9:30 PM EDT
Completed Phase 2 Interventional

Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion

NCT00073554
View directory record Official record
Conditions
Arterial Occlusive Diseases, Peripheral Vascular Diseases, Thrombosis
Interventions
Alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2009 · Synced Sep 30, 2026, 9:30 PM EDT
Completed Not applicable Interventional Results available

EXCEL Clinical Trial

NCT01205776
View directory record Official record
Conditions
Chronic Coronary Occlusion, Unprotected Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
Percutaneous Coronary Intervention, CABG
Device · Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Sep 30, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

NCT00180479
View directory record Official record
Conditions
Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent, TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 56 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Sep 30, 2026, 9:30 PM EDT
Recruiting Phase 3 Interventional

Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

NCT07318610
View directory record Official record
Conditions
Peripheral Artery Disease (PAD)
Interventions
REGN7508, REGN9933, Placebo, Rivaroxaban
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
20
States / cities
Alexander City, Alabama • Avondale, Arizona • Little Rock, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Sep 30, 2026, 9:30 PM EDT
Completed Phase 4 Interventional Results available

Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients

NCT01823510
View directory record Official record
Conditions
Type-2 Diabetes Mellitus, Coronary Artery Disease
Interventions
Ticagrelor + Aspirin, Clopidogrel + Aspirin
Drug
Lead sponsor
Juan J Badimon
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Sep 30, 2026, 9:30 PM EDT
Completed Not applicable Interventional Results available

A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)

NCT01923740
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
XIENCE V EECSS, Absorb BVS System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Sep 30, 2026, 9:30 PM EDT
Withdrawn Phase 4 Interventional

ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion

NCT00407940
View directory record Official record
Conditions
Arterial Occlusive Disease, Intermittent Claudication
Interventions
Lower extremity Atherectomy and Cryoplasty
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 30, 2026, 9:30 PM EDT
Completed Phase 4 Interventional Results available

Pharmacogenomics of Antiplatelet Response - II (PARes-II)

NCT01894555
View directory record Official record
Conditions
Atherothrombosis
Interventions
Aspirin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Sep 30, 2026, 9:30 PM EDT
Withdrawn No phase listed Observational

Impact of Anti-platelet Drug Exposure on Platelet mRNA Splicing in Healthy Subjects

NCT04088123
View directory record Official record
Conditions
Thrombosis; Artery
Interventions
Ticagrelor Oral Tablet [Brilinta]
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 70 Years
Timeline
2020
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 30, 2026, 9:30 PM EDT
Completed Phase 1 Interventional

MRI to Detect Embolism Following Angiography and Angioplasty-Stenting of the Renal Artery

NCT00027469
View directory record Official record
Conditions
Renal Artery Obstruction, Kidney Disease
Interventions
MRI
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Sep 30, 2026, 9:30 PM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants

NCT00265005
View directory record Official record
Conditions
Thrombosis
Interventions
alteplase
Drug
Lead sponsor
University of Louisville
Other
Eligibility
28 Weeks to 66 Weeks
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 30, 2026, 9:30 PM EDT
Recruiting Phase 3 Interventional

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

NCT07410117
View directory record Official record
Conditions
Cancer-Associated Thrombosis (CAT)
Interventions
REGN7508, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Hialeah, Florida • North Miami Beach, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Sep 30, 2026, 9:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Radiation Dose From Computed Tomography Before and After Implementation of a High Pitch Dual Spiral Technique

NCT01111760
View directory record Official record
Conditions
Atherosclerosis of Coronary Artery, Cardiovascular Disease, Pulmonary Embolism, Aortic Aneurysm Without Mention of Rupture Nos
Interventions
Not listed
Lead sponsor
Michael Gallagher
Other
Eligibility
Not listed
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Sep 30, 2026, 9:30 PM EDT
Terminated Phase 4 Interventional Results available

Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk

NCT00559988
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Stroke, Embolism, Systemic Arterial, Major Bleeding
Interventions
Home Monitoring Guided OAC, Physician-Directed OAC
Drug
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
73
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 70 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 30, 2026, 9:30 PM EDT
Completed Phase 4 Interventional

Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease

NCT02476526
View directory record Official record
Conditions
Chronic Kidney Disease, Pulmonary Embolism, Renal Artery Stenosis, Pulmonary Cancer
Interventions
Low Volume iso-osmolar non-ionic radio contrast medium, Acetylcysteine Inhalation, Sodium Bicarbonate Solution, 64-MDCT Scanning
Drug · Procedure
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 30, 2026, 9:30 PM EDT
Completed Phase 3 Interventional

Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries

NCT00115999
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Sep 30, 2026, 9:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nattokinase Atherothrombotic Prevention Study

NCT02080520
View directory record Official record
Conditions
Prevention of Subclinical Atherosclerosis Progression, Prevention of Cognitive Decline
Interventions
Nattokinase, Placebo
Dietary Supplement · Other
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 100 Years
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 30, 2026, 9:30 PM EDT
Completed Phase 4 Interventional Results available

Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis

NCT02053909
View directory record Official record
Conditions
Saphenous Vein Graft Disease
Interventions
Aspirin, Ticagrelor
Drug
Lead sponsor
Boca Raton Regional Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Sep 30, 2026, 9:30 PM EDT